SELANK Research Protocol Reference
A compilation of published research protocol parameters. For laboratory reference only — not a protocol recommendation.
⚠ FOR RESEARCH REFERENCE ONLY — NOT A PROTOCOL RECOMMENDATION. This page summarizes published research parameters and does not constitute guidance for human use. No validated human protocols exist for SELANK. All data derives from preclinical studies. See our full disclaimer.
Protocol Overview
FOR RESEARCH REFERENCE ONLY - NOT MEDICAL ADVICE
Selank is a synthetic heptapeptide derived from tuftsin that researchers have investigated for its potential anxiolytic and nootropic properties. Studies suggest this compound may modulate GABA neurotransmission and influence stress response pathways (PMID: 21493795). Research protocols have primarily focused on intranasal administration due to improved CNS bioavailability compared to systemic routes. This information is for educational purposes only and should never be used to guide personal supplementation decisions.
Administration & Routes
RESEARCH CONTEXT ONLY
Studies have explored intranasal administration as the primary delivery method, with researchers noting improved CNS penetration compared to subcutaneous routes. Clinical investigations have utilized specialized nasal spray formulations to ensure consistent dosing (PMID: 21493795). Some research protocols have also examined subcutaneous administration, though this route may result in rapid plasma clearance. All administration details are for research reference only.
Dosing Schedule Reference
FOR RESEARCH REFERENCE ONLY
Clinical studies investigating generalized anxiety disorder have explored intranasal doses ranging from 0.15-0.3 mg/day (PMID: 21493795). Research protocols typically divide daily doses into 2-3 administrations due to the compound's short plasma half-life. Some studies suggest morning administration may optimize anxiolytic effects while minimizing sedation. These are research observations only and not dosing recommendations.
Cycling & Duration
RESEARCH REFERENCE ONLY
Limited research data exists on optimal cycling protocols for Selank. Some studies suggest continuous daily administration for 2-4 week periods, though researchers have noted the need for washout periods to assess baseline anxiety levels. The compound's short half-life may necessitate different cycling approaches compared to longer-acting anxiolytics. Cycling information is for research context only.
Monitoring Parameters
FOR RESEARCH PURPOSES ONLY
Research protocols have monitored anxiety scales (Hamilton Anxiety Rating Scale), cognitive performance batteries, and sleep quality assessments. Studies suggest tracking nasal irritation with intranasal administration and monitoring for excessive sedation at higher doses. Some research has included cortisol measurements to assess stress response modulation. Monitoring parameters are research observations only.
Combinations & Stacks
RESEARCH REFERENCE ONLY
Some research has explored Selank in cognitive enhancement stacks, though limited published data exists on specific combinations. Studies suggest potential synergistic effects with other GABAergic compounds, though researchers emphasize the need for careful monitoring of sedative effects. The compound's anxiolytic properties may complement other nootropic agents in research settings. Combination data is for research reference only.